FDA advisors vote 9 to 6 to approve mipomersen for homozygous FH

The vote came down to a balance over the relative risks and safety of drug, with some panelists not thrilled about the modest reduction of LDL-cholesterol levels and the increased risk of liver disease. In the end, though, they felt that this patient population needs all the help they can get in lowering their risk of cardiovascular events.

via The Heart